^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG6129

    i
    Other names: RG6129, RO7444973
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, MAGE-A4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov)
    P1, N=23, Terminated, Hoffmann-La Roche | N=260 --> 23 | Trial completion date: Feb 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Jul 2023; The study was terminated due to program discontinuation.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    Actemra IV (tocilizumab) • RG6129
    over1year
    A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov)
    P1, N=260, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Feb 2024 | Trial primary completion date: Oct 2026 --> Feb 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    Actemra IV (tocilizumab) • RG6129
    over2years
    A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    Actemra IV (tocilizumab) • RG6129
    over2years
    A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov)
    P1, N=260, Not yet recruiting, Hoffmann-La Roche
    New P1 trial
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    Actemra IV (tocilizumab) • RG6129